Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025:129:103-118.
doi: 10.1007/978-3-031-97242-3_6.

Immunotherapy in Glioblastoma

Andrew Williams  1 , Rimas V Lukas  2
Affiliations
Review

Immunotherapy in Glioblastoma

Andrew Williams et al. Cancer Treat Res. 2025.

Abstract

Immunotherapies continue to hold promise for the treatment of glioblastoma, a malignant central nervous system tumor. Thus far, success utilizing this approach has been limited. Negative trials with vaccines and immune checkpoint inhibitors have been unable to demonstrate improvement in survival, however, they have provided insights into hurdles which need to be overcome. Ongoing investigations into modulation of the highly suppressed tumor immune microenvironment, direct simulation of the immune system for proinflammatory effect, and the use of cellular therapies will help inform future therapeutic directions.

Keywords: Cellular therapy; Checkpoint inhibitor; Glioblastoma; Immunotherapy; Tumor microenvironment; Vaccine.

PubMed Disclaimer

References

    1. Price M, Ballard C, Benedetti J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro-Oncology. 2024;26(Suppl_6):vi1–vi85. https://doi.org/10.1093/neuonc/noae145 . - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330 . - DOI - PubMed
    1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–202. https://doi.org/10.1016/j.ejca.2012.04.011 . - DOI - PubMed
    1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial [published correction appears in JAMA. 2018 May 1;319(17):1824. doi: 10.1001/jama.2018.3431.]. JAMA. 2017;318(23):2306–16. https://doi.org/10.1001/jama.2017.18718 . - DOI - PubMed - PMC
    1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43. https://doi.org/10.1001/jama.2015.16669 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources